Churbz: Gerald is moving LymPro forward in a very conservative and reliable way, from a scientific stand point. They don't want to skip any steps or make any promises prematurely. After all, by buying out Georgetown's blood test assays, they have essentially cornered the AD blood test market. They don't need to rush things and stub their toe. They're in the cat bird seat.

Lympro will start making pharma sales with whatever data they currently have. Gerald should be commended for his wisdom in the careful methodical way he is bringing this powerful blood test to market.

Maybe someday I'll have a face to face with Gerald again and talk to him about the importance of managing shareholder expectations. But our science is solid and I don't think some candy ass multivariant math formula is as important as we've all been thinking. The univariant data will be enough to move us forward now.